Cancer/testis antigen 1 (119-143)

Cancer/testis antigen 1 (119-143) is a synthetic peptide fragment derived from a well-characterized region of the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. As a member of the cancer/testis antigen family, this peptide is notable for its restricted expression in various malignancies and limited presence in normal adult tissues, primarily the testis. The 119-143 amino acid sequence represents an immunologically relevant epitope, making it a valuable tool for diverse research applications in tumor immunology, antigen processing, and peptide-based assay development. Its defined sequence and immunogenic properties provide a foundation for studying antigen-specific immune responses and for advancing peptide-focused investigations in cancer biology.

Epitope mapping: The 119-143 fragment of CTAG1 is frequently used in epitope mapping studies to identify and characterize T-cell and B-cell recognition sites within the NY-ESO-1 antigen. Researchers employ this sequence to delineate the specific regions of the protein that elicit immune responses, aiding in the understanding of antigen presentation and immune targeting in oncological contexts. By utilizing this peptide in mapping assays, investigators can pinpoint immunodominant epitopes, which is critical for designing targeted immunotherapies and refining diagnostic tools.

Immunogenicity assessment: As an established immunogenic region, Cancer/testis antigen 1 (119-143) is widely implemented in immunogenicity testing protocols. It serves as a model antigen for evaluating T-cell activation, cytokine production, and proliferation in vitro. The peptide's ability to stimulate antigen-specific cytotoxic T lymphocytes (CTLs) is particularly valuable for preclinical studies focused on monitoring immune responsiveness and optimizing vaccine candidates or adoptive cell transfer strategies in a controlled research environment.

Peptide-MHC binding studies: The defined sequence of this peptide enables detailed investigations into peptide-major histocompatibility complex (MHC) interactions. Scientists use it to assess binding affinities and stabilities of peptide-MHC complexes, providing crucial insights into antigen processing and presentation pathways. Such studies facilitate the selection of optimal peptide epitopes for immunotherapeutic development and enhance understanding of the molecular determinants governing immune recognition in cancer.

Assay development: Cancer/testis antigen 1 (119-143) is frequently incorporated into the design and validation of immunological assays, including enzyme-linked immunospot (ELISPOT), enzyme-linked immunosorbent assays (ELISA), and flow cytometry-based detection systems. Its well-defined immunological properties make it an ideal positive control or reference standard for evaluating assay sensitivity, specificity, and reproducibility in the context of cancer antigen detection and immune monitoring.

Peptide synthesis and modification research: The 119-143 peptide provides a valuable template for synthetic modification and structure-activity relationship (SAR) studies. Researchers utilize this fragment to investigate the effects of amino acid substitutions, post-translational modifications, or peptide conjugation techniques on antigenicity and immune recognition. Such work advances the rational design of next-generation peptide-based reagents and supports the optimization of molecular probes for cancer research and immunological applications.

1. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

2. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

3. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

4. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma